期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利妥昔单抗联合CTOP化疗治疗感染乙肝病毒恶性淋巴瘤的临床观察 被引量：8

下载PDF
导出
摘要 目的探讨利妥昔单抗联合CTOP化疗(R-CTOP方案)治疗感染乙肝病毒的非霍奇金淋巴瘤(NHL)患者的安全性。方法将42例NHL(B细胞性)患者分为A、B两组,两组均接受4～8个疗程的R-CTOP方案化疗,其中A组(12例)为感染乙肝病毒患者,在化疗同时加服拉米夫定抗病毒治疗;B组(30例)为非感染乙肝病毒组,单用化疗。疗程结束后观察两组疗效及肝功能异常发生情况。结果 A组完全缓解(CR)率为81.5%,B组CR率为83.4%,差异无统计学意义(P>0.05)。Ⅰ～Ⅱ级肝功能损害发生率A组为15.5%,B组为18.5%,差异无统计学意义(P>0.05)。A组中有1例发生HBV再激活。结论感染乙肝病毒的NHL患者在用R-CTOP方案化疗期间配合使用足疗程的拉米夫定抗病毒治疗是安全的。
作者 李小亮 王玫玫 朱卫健 谢云 李志新
机构地区 广东省珠海市人民医院血液科
出处 《广东医学》 CAS CSCD 北大核心 2012年第18期2836-2837,共2页 Guangdong Medical Journal
关键词 非霍奇金淋巴瘤 利妥昔单抗 乙型肝炎病毒 化疗
分类号 R733.105 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1HAINSWORTH J D, BURRIS H A, MORRISSEY L H, et al. Rituximab monoclonal antibody as initial systemic therapy for pa- tients with lowgrade non - Hodgkin lymphoma[ J]. Blood, 2000, 95 (10) : 3052 - 3056.
  • 2张之南.血液病诊断及疗效标准[M].2版.天津:天津科学技术出版社,1990:303.
  • 3YEO W, CHAN P K S, ZHONG S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemo- therapy: a prospective study of 626 patients with identificiation of risk factors[J]. J Med Vinol, 2000, 62(3) : 299 -307.
  • 4DERVITE I, HOBER D, MOREL P. Acute hepatitis B in a pa- tient with antibodies to hepatitis B surface antigen who was receiv- ing rituximab[ J]. N Engl J Med, 2001, 344(1) : 68 -69.
  • 5景红梅,田磊,李德津,克晓燕.利妥昔单抗联合化疗后乙型肝炎病毒携带者肝功能异常临床分析(附5例报告)[J].北京医学,2007,29(9):534-536. 被引量：8
  • 6TSUTSUMI Y, TANAKA J, KAWAMURA T, et al. Possible effi- cacy of lamivudine treatment to prevent hepatitis B virus reativation due to fituximab therapy in a patient with non - Hodgkin's lym- phoma[ J ]. Ann nematol, 2004, 83 ( 1 ) :58 - 60.
  • 7DERVITE I, HOBER D, MOREL P. Acute hepatitis B in a pa- tient with anti - bodies to hepatitis B surface antigen who was re- ceiving rituximab[ J]. N Engl J Med, 2001,344(1) : 68 -69.

二级参考文献8

  • 1Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription3 (STAT3)activity in B-Non-Hodgkin's lymphoma through inhibition of the interleukin10autocrine/ paracrine loop and results in down-regulation of Bcl-2and sensitization to cytotoxic drug. Cancer Reseach, 2001, 61:5137-5144.
  • 2Hainsworth JD, Burris HA, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with lowgrade non-Hodgkin lymphoma. Blood, 2000, 95:3052 - 3056.
  • 3Coiffier B, Lepage E, Briere J, et al. CHOP Chmotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 2002, 24:235-242.
  • 4张之南．血液病诊断及疗效标准．2版．天津科学技术出版社，1990.303．
  • 5Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol, 2002, 3:333 - 340.
  • 6Berte R, Vallisa D, Civardi G, et al. Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large Bcell non-Hodgkin's lymphoma. Acta Haematologica, 2001, 106:141 - 142.
  • 7Mimidis K, Tsatalas C, Margaritis D, et al. Efficacy of lamivudine in patients with Hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B. Acta Haematologica, 2002, 107:49 - 51.
  • 8Matano S, Kobayashi K, Ohta H, et al. Chemotherapy combined with interferon-alpha in hepatitis B virus carriers with nonHodgkin's lymphoma. Acta Haematologica, 2002, 107:46 - 48.

共引文献7

同被引文献62

  • 1刘伟红,李琳洁,许能文,刘志国.化疗辅助吡柔比星治疗老年恶性淋巴瘤患者50例效果分析[J].中国生化药物杂志,2014,34(2):95-96. 被引量：7
  • 2张蕊,于锦香,李艳,潘登,高然,高峰,翟明.氟达拉滨联合米托蒽醌与CHOP方案治疗恶性淋巴瘤的疗效比较[J].中国实用内科杂志,2007,27(11):851-852. 被引量：4
  • 3吕书晴,杨建民,宋献民,陈莉,章卫平,倪雄,许晓倩,王健民.氟达拉滨为主的联合化疗方案治疗低度恶性非霍奇金淋巴瘤的临床观察[J].中华肿瘤杂志,2007,29(9):710-712. 被引量：10
  • 4Anderson LA, Pfeiffer R, Warren JL, et al. Hematopoietic malig- nancies associated with viral and alcoholic hepatitis [ J ]. Cancer Epidemiol Biomarkers Prey ,2008,17 ( 11 ) :3069 - 3075.
  • 5Uleiekas Yood M, Quesenberry CP, Guo D, et al. Incidence of non-Hodgkin' s lymphoma among individuals with chronic hepati- tisB virus infection [ J ]. Hepatology,2007,46 ( 1 ) : 107 - 112.
  • 6Fwu CW, Chien YC, Nelson KE ,et al. Mortalityafter chronic hepa- titis B virus infection: alinkage study involving 2 millionpamus women from taiwan[ J]. J Infect Dis,2010,201 (7) :1016 -1023.
  • 7Cheson BD, Homing S J, Coiffier B, et al. Report of an internation- al workshop to standardize response criteria for non-Hodgkin' s lymphomas [ J ]. J Clin Oncol, 1999,17 (4) : 1244 - 1253.
  • 8Perry MC. Hepatotoxicity of chemotherapeutic agents [ J ]. Semin Oncol, 1982,9 ( 1 ) :65 - 74.
  • 9Ueo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab [ J ]. J Clin Oncol, 2009,27(4) :605 -611.
  • 10Forero A,Lobuglio AF. History of antibody therapy for non-Hodgkin' s lymphoma[J]. Semin Oncol,2003,30(6 Suppl 17) :1-5.

引证文献8

二级引证文献30

广东医学
2012年 第18期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部